Skip to content

Effect of growth hormone on muscle function

Effect of growth hormone (GH) on anaerobic capacity: a double blind placebo-controlled study in growth hormone deficient (GHD) adults

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12615000046505
Enrollment
19
Registered
2015-01-21
Start date
2013-02-19
Completion date
2014-04-09
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Aerobic energy powers endurance exercises e.g. jogging, long distance running etc. and it is used as a measure of fitness. On the other hand, initiation of any activity (e.g. rushing for a bus, climbing stairs) relies on anaerobic energy that is provided by preformed energy in form of phosphocreatine and glycolysis (breakdown of glucose) that occurs in absence of oxygen. Hence, individuals with inadequate anaerobic energy levels usually struggle to carry out their activities of daily living and suffer from chronic fatigue. What regulates the Anaerobic Energy System (AES) is not well studied and the factors that enhance AES apart from physical training are not known. Adults with Growth Hormone Deficiency (GHD) typically suffer from chronic fatigue and loss of vitality, symptoms suggesting impairment of the AES. These symptoms improve with GH replacement. However, the mechanisms underlying the symptomatology and how it is improved are poorly understood. New research shows that GH plays a vital role in energy provision. A recent study showed that administration to healthy subjects with GH enhanced sprinting, which is a marker of anaerobic capacity. However, GH did not improve any other measures of physical performance. Another research studied the effects of GH treatment in GHD subjects at a cellular level and found that GH favored the use of glucose (anaerobic glycolysis) over fat as a fuel for energy provision in muscle cells. These studies indicate that GH may have a positive role in regulating the AES. The main aims of this study are to investigate the effects of GH on anaerobic capacity and genes governing energy metabolism in skeletal muscle, and study the relationship between the AES and physical function.

Interventions

A 2-month double-blind placebo controlled GH treatment (0.5mg/d) study with a crossover at 1 month, followed by an open-label active treatment phase (0.5mg/d) for 6 months in 20 GHD adults. There is no 'wash out' period between treatment periods. 4 weeks of Placebo treatment is adequate to wash out any GH effect on Wingate performance based on pilot data from our laboratory. GH is administered via subcutaneous injection. Adherence to the intervention will be assessed by counting empty drug vials

A 2-month double-blind placebo controlled GH treatment (0.5mg/d) study with a crossover at 1 month, followed by an open-label active treatment phase (0.5mg/d) for 6 months in 20 GHD adults. There is no 'wash out' period between treatment periods. 4 weeks of Placebo treatment is adequate to wash out any GH effect on Wingate performance based on pilot data from our laboratory. GH is administered via subcutaneous injection. Adherence to the intervention will be assessed by counting empty drug vials and measuring plasma IGF1 levels.

Sponsors

Princess Alexandra Hospital
Lead SponsorHospital

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

Growth hormone deficiency (diagnosed as per internationally accepted criteria)

Exclusion criteria

1. Cardiac, respiratory, renal, liver or neurological disease 2. Pregnancy 3. Malignancy 4. Inability to consent

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026